You are here

Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome.

Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM

Canadian Journal of Cardiology 2014 May;30(5):534-543. 

Editors' comments: Dr. A. Snegovoy

Developments in drug therapies and new drugs associated with the development of adverse events that are "new" mechanism of pathogenesis and require special tactics of correction. 
Development of hypertension on the background of targeted therapy may cause changes in the intensity of treatment and serious complication, such as stroke. 
The article presents a modern view of this problem, and also considers the possibility of rational therapy which may be useful in clinical practice.